Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | AGER | Q15109 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886514 | 0.87 | KDM4E (0.50) | ALDH1A1KDM4EHIF1ANPC1RAB9A | |
| SCHEMBL5886291 | 0.85 | ALDH1A1 (0.48) | ALDH1A1KDM4ENPC1RAB9AGAA | |
| SCHEMBL5886262 | 0.84 | ALDH1A1 (0.47) | ALDH1A1KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL5886451 | 0.84 | ALDH1A1 (0.49) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL5886271 | 0.83 | ALDH1A1 (0.54) | DHODHALDH1A1KDM4EHIF1ANPC1 | |
| SCHEMBL5886304 | 0.83 | ALDH1A1 (0.51) | DHODHALDH1A1PTGER1NPC1RAB9A | |
| SCHEMBL5886500 | 0.83 | KDM4E (0.52) | ALDH1A1KDM4ENPC1RAB9AGAA | |
| SCHEMBL5886309 | 0.82 | ALDH1A1 (0.47) | ALDH1A1KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL5886444 | 0.82 | ALDH1A1 (0.47) | ALDH1A1KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL5886382 | 0.81 | PTGES (0.44) | ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132419-B2 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2006-11-07 | — | — | US | claimed |
| US-20050143383-A1 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2005-06-30 | — | — | US | claimed |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | claimed |
| US-7132419-B2 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20050143383-A1 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143383-A1 | Pharmaceutical compounds | CHRNA10, OPRM1, SCN10A | DHODH 3177/4885ALDH1A1 3766/4885ELANE 3818/4885 |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | TOP1, TOP2A, TOP2B | DHODH 535/4885ALDH1A1 2334/4885ELANE 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.